Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by XiaoRong Zhong
MiR-4653-3p and Its Target Gene FRS2 Are Prognostic Biomarkers for Hormone Receptor Positive Breast Cancer Patients Receiving Tamoxifen as Adjuvant Endocrine Therapy
Oncotarget
Oncology
Related publications
Low P27 Expression Predicts Early Relapse and Death in Postmenopausal Hormone Receptor-Positive Breast Cancer Patients Receiving Adjuvant Tamoxifen Therapy
Clinical Cancer Research
Cancer Research
Oncology
The Aromatase Inhibitors as Adjuvant Therapy for Hormone Receptor-Positive Breast Cancer
Journal of the National Comprehensive Cancer Network : JNCCN
Medicine
Oncology
Neoadjuvant Endocrine Therapy for Estrogen Receptor–Positive Breast Cancer
JAMA Oncology
Cancer Research
Oncology
Adjuvant Endocrine Monotherapy for Postmenopausal Early Breast Cancer Patients With Hormone-Receptor Positive: A Systemic Review and Network Meta-Analysis
Breast Cancer
Nuclear Medicine
Radiology
Pharmacology
Oncology
Imaging
Medicine
New Strategies in Metastatic Hormone Receptor–Positive Breast Cancer: Searching for Biomarkers to Tailor Endocrine and Other Targeted Therapies
Clinical Cancer Research
Cancer Research
Oncology
Hedgehog Acyltransferase as a Target in Estrogen Receptor Positive, HER2 Amplified, and Tamoxifen Resistant Breast Cancer Cells
Molecular Cancer
Cancer Research
Oncology
Molecular Medicine
Endocrinology and Hormone Therapy in Breast Cancer: New Insight Into Estrogen Receptor-Α Function and Its Implication for Endocrine Therapy Resistance in Breast Cancer
Breast Cancer Research
Cancer Research
Oncology
Overall Survival and Progression-Free Survival With Endocrine Therapy for Hormone Receptor-Positive, HER2-negative Advanced Breast Cancer: Review
Therapeutic Advances in Medical Oncology
Oncology
Adjuvant Endocrine Therapy in Early Postmenopausal Breast Cancer
Breast Care
Surgery
Oncology
